Elevated circulating levels of FGF-21 in insulin resistance states like obesity, type 2 diabetes, and NAFLD suggests an impairment and resistance to the actions of FGF-21 [46,50]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.